Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy

Table 1 Study characteristics according to the type of preoperative chemotherapy, type of response, overall and disease-free survivals of patients who underwent curative-intent treatment hepatectomies for colorectal liver metastases

Ref.	N1 (total)	N (surgery)	Age2 (yr)	Median FU (mo)	Preoperative chemotherapy	R0 (%)	Preoperative chemotherapy response (%)	Median OS (mo)	1-yr OS (%)	3-yr OS (%)	5-yr OS (%)	1-yr DFS (%)	3-yr DFS (%)	5-yr DFS (%)
Allen et al[28], 2003	106	52	59	30	5-FU	82.6	R: 12 (26); S: 17 (37); P: 17 (37)							RS: 0.87; P: 0.38
Adam et al[29], 2004	131	131	59.5 (32-78)	33.1	5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan	90	R: 58 (44); S: 39 (30); P: 34 (36)	O: 30	R: 0.95; S: 0.92; P: 0.63	R: 0.55; S: 0.44; P: 0.12	R: 0.37; S: 0.3; P: 0.08	R: 0.52; S: 0.33; P: 0.23	R: 0.32; S: 0.23 P: 0.07	R: 0.21; S: 0.17; P: 0.38
Neumann et al[2], 2009	160	160	R: 59 (35-77); S: 60 (35-73); P: 60 (36-78)	28.8	5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/5-FU + Oxaliplatin + Irinotecan + antiEGFR or antiVEGF	72.5	R: 44 (27.5); S: 20 (12.5) P: 90 (60)	R: 37.2; S: 44.4; P: 38.1	O: 0.88	O: 0.53	R: 0.34; S: 0.44; P: 0.36
Gallagher et al[30], 2009	111	111	61 (27-85)	63	5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/Others	84.6	R: 47 (42.3); S: 52 (47); P: 18 (16)	R: 58; S: 65; P: 61			R: 0.5; S: 0.51; P: 0.61
Tamandl et al[18], 2009	244	29	73.1 (70.1-83)	34	5-FU/Capecitabine		R: 13 (44); S: 7 (24) P: 90 (31)				R: 0.64; S: 0.36; P: 0
de Haas et al[35], 2010	119	119	61 (51-71)	34	5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/Others	59.6	R: 72 (60); S: 28 (24); P: 19 (16)	R: 34; S: 32; P: 20		R: 0.42; S: 0.46; P: 0.36	R: 0.29; S: 0.28; P: 0.07		R: 0.09; S: 0.09; P: 0.07
Brouquet et al[31], 2011	60	60	59 (48-70)	32	5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/5-FU + Oxaliplatin or Irinotecan + antiEGFR or antiVEGF	80	R: 22 (37); S: 22 (37); P: 16 (27)	R: 41.7; S: 23; P: 15.9	O: 0.83	O: 0.41		O: 0.37	O: 0.11
Giuliante et al[7], 2014	130	113	58.6 (36-81)	19	Oxaliplatin-based/Irinotecan-based/Oxaliplatin + Irinotecan-based/associated antiEGFR/associated antiVEGF	76.1	P: 67 (61.5); R: 36 (32.1); P: 7 (6.35)	O: 43			O: 0.32
Pugh et al[36], 2016	110	63	CA: 65; CC: 64	CA: 14.5; CC: 14.2	CAPOX/Oxaliplatin-MdG/Irinitecan-MdG/CAPOX + Cetuximab/Oxaliplatin-MdG + cetuximab/Irinitecan-MdG + cetuximab	100	O: 63 (100)	CA: 29; CC: 19.9
Lim el al[37], 2016	155	146	65 (33-83)	36	5-FU/Capecitabine/5-FU + Oxaliplatin/5-FU + Irinotecan	85.6	R: 72 (46.5); S: 48 (31); P: 26 (16.8)
Imai et al[38], 2016	846	691	61 (28-89)	44.2	5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/ + antiEGFR or -antiVEGF or Panitumumab	34.1	RS: 501(72.5); P: 46 (6.6)			O: 64.7	O: 49.6		O: 30.1	O: 19.1
Adam et al[9], 2017	6415	6415	G1: 61.6; G2: 61.4	30.1	5-FU + Oxaliplatin/5FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/5-FU + Oxaliplatin + Irinotecan/ + antiEGFR or -antiVEGF or Panitumumab		R: 4710 (73.4); S: 1289 (20.1); P: 416 (6.5)	G1: 58.9; G2: 58.6		G1: 71; G2: 76	G1: 49; G2: 49		G1: 32; G2: 27	G1: 23; G2: 15
Vigano et al[33], 2018	128	128	RS: 61; P: 62	30	5-FU + Oxaliplatin/5FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/ + antiEGFR or -antiVEGF or Panitumumab		RS: 96 (75); P: 32 (25)			RS: 52.4; P: 0.23			RS: 21.6; P: 6.3
Ruzzenente et al[39], 2019	784	784	59.4 (51.3-67.8)	-	5-FU + Oxaliplatin/5FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/ + antiEGFR or -antiVEGF or Panitumumab		RS: 405 (51.6); P: 314 (40.1)				RS: 51.6; P: 40.1
Brunsell et al[40], 2019	142	142	67 (21-80)	37	5-FU + Oxaliplatin/5FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/+ antiEGFR or -antiVEGF or Panitumumab	37.8	R: 66 (46.5); S: 63 (44.4); P: 13 (9.1)	R: > 60; S: 47; P: 33

¹Total per study.

²Median (range) or mean plus standard deviation as described by the authors.

FU: Follow-up; 5-FU: 5-fluorouracil; R: Disease response group; S: Stable disease group; P: Progression disease group; RS: Response and stable disease group; O: Overall; OS: Overall Survival; DFS: Disease-Free Survival; MdG: Modified de Gramont; CA: Chemotherapy alone group; CC: Chemotherapy plus cetuximab group; G1: Resection after first-line chemotherapy group; G2: Resection after second-line chemotherapy group.